Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Zevra Therapeutics (ZVRA).
Zevra Therapeutics has announced promising results from their Phase 2 clinical trial of KP1077, a treatment for Idiopathic Hypersomnia, showing the drug to be safe and well-tolerated. Patients experienced meaningful improvements in daytime sleepiness and other symptoms, with the trial providing essential data for advancing to a Phase 3 trial. The company is preparing to discuss next steps with the FDA, amidst caution about forward-looking statements, emphasizing the inherent risks and uncertainties in drug development.
See more data about ZVRA stock on TipRanks’ Stock Analysis page.